The Gamaleya Center will be able to modify its coronavirus vaccine within a week if the vector technology is registered, as Alexander Ginzburg, the director of the Center, said on Sunday in an interview with the Rossiya-1 TV channel.
“If a new strain, with a dramatically different sequence of S-protein that binds to our receptors, emerges, then, most likely, it will be necessary to use updated vaccine variants. If the vector technology is registered, then we can really respond to the new threats within a week,” TASS quotes him as saying.
The director of the Center also noted that the antibodies in those vaccinated with Sputnik V are more active in their action against the virus than the antibodies in those who recovered from COVID-19. According to him, “memory cells” can protect the body from the virus, but antibodies are more effective against new strains.
As Ginzburg said earlier, the Gamaleya Center specialists have developed a technology that makes it possible to quickly create vaccines effective against several variants of COVID.
